Kristi Rosa | Authors

April 14, 2021

For patients with recurrent platinum-resistant epithelial ovarian cancer who were naïve to PD-1/PD-L1 inhibition, the combination treatment of tislelizumab plus sitravatinib showed early antitumor activity while maintaining a manageable safety profile.

April 14, 2021

Zenocutuzumab has been shown to block the growth and cause the death of NRG1 fusion–positive cell lines, and to induce tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.

April 10, 2021

Frontline treatment with tebentafusp significantly improved overall survival in patients with metastatic uveal melanoma, according to data from the phase 3 IMCgp100-202 trial.

February 11, 2021

Improvement in overall survival (OS) for patients with metastatic non–clear cell renal cell carcinoma (RCC) was linked with first-line treatment using immune checkpoint inhibitor–based regimens versus select targeted therapies

January 29, 2021

Results from the phase 3 ADAURA trial found extended disease-free survival for patients, irrespective of previous adjuvant chemotherapy received or disease stage.

January 21, 2021

Encouraging efficacy and safety outcomes were reported at the 2021 Gastrointestinal Cancers Symposium when infigratinib was used to treat FGFR2 fusion–positive cholangiocarcinomas that are refractory to chemotherapy.

December 11, 2020

Sacituzumab govitecan (Trodelvy) induced clinical benefit over physician’s choice of therapy in patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, though greater efficacy was observed in those who had a medium or high Trop-2 score.

December 10, 2020

Ribociclib plus endocrine therapy continued to show a significant overall survival improvement, while delaying subsequent chemotherapy for patients with HR+/HER2-negative breast cancer.

December 09, 2020

The use of serial circulating tumor cell enumeration was confirmed to strongly predict overall survival outcomes in patients with metastatic breast cancer.

December 08, 2020

Patients with hematologic malignancies were found to be at increased risk for significant morbidity and mortality from COVID-19, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment.